Eikos wins R&D Magazine award for CNT
transparent and conductive coatings. Eikos’ transparent conductive coating technology, branded Invisicon® has a broad range of applications in the electronics field, including flat panel displays, OLED lighting, and solar cells. In each case, Invisicon® acts as a superior alternative to traditional transparent conductive layers, including Indium Tin Oxide (ITO).

Micell Technologies receives 2006 R&D 100 Award
for its breakthrough innovation e-RESS technology. The R&D 100 Awards are presented annually by R&D Magazine to honor the world's 100 most important scientific and technical innovations. Micell shares this award with Pacific Northwest National Laboratory, a U.S. Department of Energy laboratory, managed by Battelle for the development of a supercritical fluid deposition process where by drug-eluting polymer nanoparticles are synthesized and coated onto stent supports in the deposition process to produce superiorly performing cardiac stents..

Abbott licenses Elan's NanoCrystal® Technology.
Under the License Agreement, Elan's NanoCrystal Technology may be utilized in the combination product in order to optimize bioavailability and absorption in patients. TriCor® 145 and Crestor® are both currently marketed and used to treat adults with high cholesterol. TriCor, part of a class of medications called fibrates, has been shown to predominately reduce triglycerides, a form of fat or lipid obtained through food sources, raise HDL cholesterol and lower LDL cholesterol.

Malvern Instruments buys Spectral Dimensions.
Chemical imaging adds an exciting new dimension to Malvern's particle characterization range of products and capabilities. Chemical imaging is an exciting new analytical capability that facilitaties quantitative and spatial identification of chemical species.

Applied NanoWorks inititates growth plan.
Their next stage of growth is headed by the addition of Tim Ullman to the management team as Operations Manager, with the responsibility of taking the lab scale processes for nano-scale materials and implementing the first production scale equipment and trials. The first product to be scaled up is the company’s Pinnacle Titanium Dioxide, which is sold as a dispersion of 5 nanometer particles in water. The company is also evaluating a number of sites for a material production and application development facility.

Calando Pharmaceuticals and National Cancer
Institute entered into a CRADA to further develop RNAi nanoparticle-based treatment of neuroblastoma, the most common extracranial solid tumor in children younger than five years of age.

Arkema opens Carbon Nanotube Pilot Plant at
its Lacq Research Center, Pyrenees-Atlantiques, SW France. Arkema's pilot plant is designed to produce carbon nanotubes in semi-industrial volumes at a cheaper cost than those manufactured today in the laboratory. With this new pilot plant, Arkema is looking to the genuine commercial development of carbon nanotubes to fulfill the expectations of converters in the thermoplastics, epoxy, elastomer and coating sectors.

Novartis and Alnylam enter collaboration
to address pandemic flu with an RNAi-based therapeutic. RNAi is induced by small, double-stranded RNA molecules and one method to activate RNAi is with chemically synthesised small interfering RNAs, or siRNAs, which are double-stranded RNAs that are targeted to a specific disease-associated gene. The siRNA molecules are used by the natural RNAi machinery in cells to cause highly targeted gene silencing.

Oxonica acquires Nanoplex Technologies
A U.K. start-up from Oxford University, Oxonica, focusing on nanoparticle addititves for diesel fuel and sunscreens, is acquireing Nanoplex Technologies for $18-$21M in Oxonica stock. Oxonica's US operations will be headed by Nanoplex Technologies CEO and founder Dr. Michael Natan.

Keystone Nano named International Winner
of the Second Annual International Nanotechnology Business Idea Competition. Organizers of the competition include three Case Western Reserve University programs and NorTech's Nano-Network. Sponsors include ASM International, Nanofilm, Ferro Corp, Case, Frest City Enterprises, The Partnerships for Innovation Program of the National Science Foundation, and the Joseph P. & Nancy F. Keithley Foundation. The $75,000 award was given in recognition of Keystone Nano's Molecular Dots that are 5-50 nm in diameter and that can deliver therapeutic drugs as well as functioning as imaging agents. The Keystone Nano management team is headed by Jeff Davidson, CEO, Dr. James Adair, Chief Scientific Officer, Dr. Mark Kester, Chief Medical Officer, and Robert Cornwall, Vice-President of Operations.

Invitrogen Corporation, a leading life science
company providing innovative technologies to support disease research, announced the acquisitions of Quantum Dot Corporation and the BioPixels(R) business unit of BioCrystal, Ltd. and the early closing of the Biosource International, Inc. (Nasdaq:BIOI) acquisition. The acquisition of Quantum Dots and BioPixels(R) bolster Invitrogen's Molecular Probes business as the leader in advanced labeling and detection technologies. Invitrogen also announced an agreement with Georgia Tech Research Corporation to exclusively license novel "nanocluster" technology. Taken together, the combination of these acquisitions and licenses will enable Invitrogen to create new innovative products that enable life science researchers to better visualize and understand cellular processes, molecular interactions, and other factors essential to diagnosing and treating disease. Terms of the acquisitions and license were not disclosed.

Nanomix awarded SBIR grant from NIH to commercialize Sensation technology.
Nanomix announced July 25, 2005 that this Phase 1 grant from the National Institute of Biomedical Imaging and Bioengineering will fund the development of novel manufacturing processes for the production of nanotube-based nanoelctronic detection devices for medical applications.

Eastman Kodak Company announces creation
of small new technology R&D unit in Cambridge (UK) following dissolution of French (Chalon) and UK (Harrow) R&D organizations. This new European Research Division will be responsible for indentifying opportunities that serve the digital needs of European markets. Kodak, once the preeminent producer of nanoparticle and particle based imaging materials (film and paper) has been steadily decreasing its employee base over the past 15 years while it attempts to refocus on digital imaging.

QuantumSphere, Inc. announced it has retained Natural Carbon, LLC
to accelerate QuantumSphere’s business development initiatives. The retention of Natural Carbon will provide QuantumSphere with seasoned business development expertise that will aggressively drive QuantumSphere’s growth, commercialization of new products and market expansion via sales of the company’s current product lines that are experiencing unprecedented demand around the world.

Copernicus Therapeutics, Inc. announced
nanoparticle DNA drug delivery technology on June 8, 2005, for brain and eye diseases. This efficient and effective non-viral DNA nanoparticle technology has been shown to be useful in introducing DNA into brain cells and into cells of the retina.

Merck, Wyeth, and Abbott obtained FDA approval for Elan nanoparticulate
drug delivery technology, as reported by Till, Simkin, and Maebius of Foley & Lardner LLP. The benefits of a nanoparticulate drug can include certain exclusivities based on FDA law and the U.S. patent code. These successes for particle-based delivery are the beginning of a burgeoning period of advances in therapy and delivery.

Cabot Corporation and Centerpoint Translucent Systems LLC
announced on May 10, 2005 that Centerpoint will exclusively manufacture translucent nanogel roofing systems to provide comforatable daylight lighting in home interiors, based on Cabot's Nanogel material, a translucent aerogel that diffusely transmits light and serves as an effective thermal insulation material..

Debiopharm and Nanocarrier form a research
collaboration on a new platinum compound using the micellar MediCelle technology of Nanocarrier. Debiopharm will fund the venture and provide Nanocarrier cash payments at particular milestones.

Venture funding for nanomaterials companies
in early 2005 was reported recently by David Forman in the April 2005 issue of smalltimes.

NanoDynamics of Buffalo, New York,
agree to expand applications and commercial use of Nanocyl S.A.'s single, double and multiwall carbon nanotubes in North America.

Copernicus Therapeutics, Inc. accounced nanoparticle DNA
drug delivery technology on June 8, 2005, for brain and eye diseases. This efficient and effective non-viral DNA nanoparticle technology has been shown to be useful in introducing DNA into brain cells and into cells of the retina.

Merck, Wyeth, and Abbott obtained FDA approval for Elan nanoparticulate
drug delivery technology, as reported by Till, Simkin, and Maebius of Foley & Lardner LLP. The benefits of a nanoparticulate drug can include certain exclusivities based on FDA law and the U.S. patent code. These successes for particle-based delivery are the beginning of a burgeoning period of advances in therapy and delivery.

Cabot Corporation and Centerpoint Translucent Systems LLC
announced on May 10, 2005 that Centerpoint will exclusively manufacture translucent nanogel roofing systems to provide comforatable daylight lighting in home interiors, based on Cabot's Nanogel material, a translucent aerogel that diffusely transmits light and serves as an effective thermal insulation material..

Debiopharm and Nanocarrier form a research collaboration
on a new platinum compound using the micellar MediCelle technology of Nanocarrier. Debiopharm will fund the venture and provide Nanocarrier cash payments at particular milestones.

Venture funding for nanomaterials companies in early 2005
was reported recently by David Forman in the April 2005 issue of smalltimes.

NanoDynamics of Buffalo, New York,
agree to expand applications and commercial use of Nanocyl S.A.'s single, double and multiwall carbon nanotubes in North America.

Altair Nanotechnologies and Bateman Engineering announce joint venture projects.
(1) Altairnano Bateman Titania brings together Altair's proprietary and patented titanium dioxide pigment manufacturing process with Bateman's engineering expertise to develop, design, construct and commission manufacturing plants to produce titanium dioxide pigment. (2) The second project is with Randsburg International Gold Corporation, a North American exploration company. This project is a raw material evaluation study to determine the suitability of its ore body for titanium dioxide pigment manufacturing. Randsburg has identified titanium dioxide pigment as one of the high-value products to be produced from ore mined at its Titan deposit in Ontario, Canada.

Nanophase Announces First Quarter 2005 Results.
Achieves positive gross margin and 25% year-over-year revenue growth.

Konarka and Evident Technologies form joint research program to develop ultra high performance power plastic.
Companies' novel polymers and quantum dots target capturing broad spectrum of both visible and invisible light.